Relative Bioavailability of Two BI 456906 Formulations After Subcutaneous Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Trial)
Latest Information Update: 22 Aug 2025
At a glance
- Drugs Survodutide (Primary)
- Indications Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 07 Aug 2025 Status changed from not yet recruiting to recruiting.
- 29 Jul 2025 New trial record